Study assessing metabolism, excretion and pharmacokinetics of a Poly (ADP-ribose) polymerase (PARP) inhibitor in patients with solid metastatic tumours
Study identifier:D0810C00010
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Open, Non-randomized, Single Centre Phase I Study to Assess the Metabolism, Excretion and Pharmacokinetics of a Single Oral 100 mg Dose of [14C]-AZD2281 (KU-0059436) in Patients with Advanced or Metastatic Solid Tumours Refractory to Standard Treatments
Medical condition
Neoplasm Metastasis
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD2281
Sex
All
Actual Enrollment
6
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Apr 2008
Primary Completion Date: 01 Oct 2008
Study Completion Date: 01 Oct 2008
Study design
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
KuDOS Pharmaceuticals Ltd (a member of the AstraZeneca Group of companies)
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
James Carmichael
KuDOS Pharmaceuticals, Ltd
